Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy

Executive Summary

Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.


Related Content

Novartis Progressing Trials For Oral Asthma Therapy In India
Orphans Dominate Products Seeking End-Of-Year Joy From CHMP
Confidence High As AstraZeneca Adds Asia To Benralizumab Territories
Positive Asthma Data Prompts Pulmagen To Seek Global Partner For CRTh2 Antagonist
GSK's Nucala Shows Promise In A Rare Systemic Vasculitis
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Teva Under Pressure As NICE Calls For More Reslizumab Analyses
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
Cornerstone accepts Chiesi proposal after long courtship
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts